Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A-Reference-Cited by-同舟云学术

Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

Published:2010-11-11 Issue:2 Volume:17 Page:185-190
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

DMOSZYNSKA A.,HELLMANN A.,BAGLIN T.,O’SHAUGNESSY D.,TRELINSKI J.,KULICZKOWSKI K.,KLOCZKO J.,HAY C.,ZAWILSKA K.,MAKRIS M.,SHAIKH-ZAIDI R.,GASCOIGNE E.,DASH C.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02414.x/fullpdf

Reference25 articles.

1. Confirmation of viral safety of dry heated Factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of UK Haemophilia Centre Directors;Rizza;Br J Haematol,1993

2. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates;Colvin;Lancet,1988

3. West nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data;Kreil;Transfusion,2003

4. Inactivation of west nile virus, vaccine virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products;Remington;Vox Sang,2004

5. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia;Yee;Lancet,1995

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review;Research and Practice in Thrombosis and Haemostasis;2019-05-20

2. Pharmacokinetic profile of Optivate ® (high‐purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease;Haemophilia;2015-11-17

3. Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins;Journal of Pharmaceutical Sciences;2013-07

4. Removal of TSE agent from plasma products manufactured in the United Kingdom;Vox Sanguinis;2012-11-21

5. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A;Haemophilia;2011-06